Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Tislelizumab for dMMR/MSI-H Non-late Stage CRC
NCT06262581Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2023
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in colorectal cancer (CRC), sponsored by Sun Yat-sen University. Primary endpoint: Pathological Complete Regression Rate at 1 year. Started Sep 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06262581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06262581.